UCSF prostate cancer specialist inducted into annual ‘Giants in Cancer Care’ class

Eric Petit, MD. Image by Marco Sanchez

Eric J. PetitMD, was announced as one of the winners of the 10th edition Cancer Care Giants® rewards. Small is recognized for his achievements in clinical practice and research in genitourinary cancers.

Small is a medical oncologist and holds the Doris and Donald Fisher Distinguished Professorship in Clinical Cancer Research as well as the Stanford W. Ascherman and Norman R. Ascherman Endowed Chair at UCSF. Small, a professor in the departments of medicine and urology, is associate director and scientific director of the UCSF Helen Diller Family Comprehensive Cancer Center (HDFCCC).

As co-leader of UCSF HDFCCC Prostate cancer programhis clinical activities and research focus on advanced prostate cancer, understanding how bodily mechanisms can create resistance to standard therapies, and developing new therapeutic approaches for patients with advanced prostate cancer .

After undergraduate studies at Stanford University, Small earned his medical degree at Case Western Reserve University School of Medicine, where he graduated with honors. During his medical studies, he completed a fellowship in pathology. He completed postgraduate training in internal medicine at Beth Israel Hospital (Boston), followed by a fellowship in hematology and oncology at UCSF.

This kind of work takes up an entire village and would not be possible without my talented and dedicated colleagues at UCSF, as well as our patients and their families.

Eric Petit, MD

Small is a member of several professional medical societies, including the American Society of Clinical Oncology (ASCO), having recently served on its board of directors, and where he is currently one of four mentors in its leadership development program. Small chairs scientific advisory boards for several other NCI comprehensive cancer centers.

“I am grateful for this wonderful honor and to be recognized for research that has led to a better understanding of resistance mechanisms in advanced prostate cancer and improved outcomes for men with advanced cancer. prostate,” Small said. “This type of work takes up an entire village and would not be possible without my talented and dedicated colleagues at UCSF, as well as our patients and their families.”

Small and his fellow inductees were recognized at the Giants of Cancer Care® 10th Anniversary Awards Ceremony June 2 in Chicago. Since 2013, the Giants of Cancer Care program, presented by OncLive, has celebrated more than 125 oncology pioneers for their groundbreaking achievements in research and clinical practice. Out of hundreds of nominations, only 14 oncologists were selected to join the prestigious Class of 2022.

“We would like to congratulate each member of this year’s class of inductees on this tremendous honor,” said Mike Hennessy Jr., President and CEO of MJH Life Sciences™, the parent company of OncLive®. “It’s no surprise that these oncologists have been recognized for their contributions and dedication to this vital practice. They are all legends in the world of oncology.

Comments are closed.